CN1489996A - 双氯芬酸钠贴剂及其制备方法 - Google Patents
双氯芬酸钠贴剂及其制备方法 Download PDFInfo
- Publication number
- CN1489996A CN1489996A CNA031295037A CN03129503A CN1489996A CN 1489996 A CN1489996 A CN 1489996A CN A031295037 A CNA031295037 A CN A031295037A CN 03129503 A CN03129503 A CN 03129503A CN 1489996 A CN1489996 A CN 1489996A
- Authority
- CN
- China
- Prior art keywords
- diclofenac sodium
- sensitive adhesive
- patch
- pressure sensitive
- polyisobutylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001193 diclofenac sodium Drugs 0.000 title claims abstract description 66
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 28
- 229920002367 Polyisobutene Polymers 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 9
- 239000004014 plasticizer Substances 0.000 claims abstract description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000005642 Oleic acid Substances 0.000 claims abstract description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000004202 carbamide Substances 0.000 claims abstract description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940041616 menthol Drugs 0.000 claims abstract description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- -1 fatty acid ester Chemical class 0.000 claims description 11
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 7
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 3
- 229940025250 camphora Drugs 0.000 claims description 3
- 239000010238 camphora Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 235000013877 carbamide Nutrition 0.000 claims description 2
- 229960005233 cineole Drugs 0.000 claims description 2
- 238000007334 copolymerization reaction Methods 0.000 claims description 2
- 235000001510 limonene Nutrition 0.000 claims description 2
- 229940087305 limonene Drugs 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229940116351 sebacate Drugs 0.000 claims description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-Ethyl-2-pyrrolidinone Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 206010070834 Sensitisation Diseases 0.000 abstract description 7
- 230000008313 sensitization Effects 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 3
- 229920000832 Cutin Polymers 0.000 abstract description 2
- 239000004902 Softening Agent Substances 0.000 abstract description 2
- 150000007524 organic acids Chemical class 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 150000003505 terpenes Chemical class 0.000 abstract description 2
- 235000007586 terpenes Nutrition 0.000 abstract description 2
- 230000007794 irritation Effects 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 238000003756 stirring Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000005030 aluminium foil Substances 0.000 description 4
- 230000035617 depilation Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003746 feather Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 150000004040 pyrrolidinones Chemical class 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000026137 Soft tissue injury Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000004760 Tenosynovitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- RLLPVAHGXHCWKJ-UHFFFAOYSA-N permethrin Chemical compound CC1(C)C(C=C(Cl)Cl)C1C(=O)OCC1=CC=CC(OC=2C=CC=CC=2)=C1 RLLPVAHGXHCWKJ-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及医药技术领域,是一种双氯芬酸钠贴剂及其制备方法。本发明贴剂包括背衬层、药物储库及保护膜,药物储库由双氯芬酸钠、压敏胶、渗透促进剂组成,压敏胶选自丙烯酸酯类和聚异丁烯类,加入增塑剂可改善粘附性能;渗透促进剂选自乙醇等有机溶剂类、油酸等有机酸类、氮酮、十二烷基硫酸钠等表面活性剂类、尿素等角质保湿与软化剂类、薄荷醇等萜烯类。本发明透皮效果好,粘贴牢固,对皮肤无刺激性和致敏性。
Description
技术领域:
本发明涉及医药技术领域,是一种双氯芬酸钠贴剂及其制备方法。
背景技术:
双氯芬酸钠系邻胺基苯甲酸类的非甾体消炎镇痛药,其作用机制与乙酰水杨酸相似,可选择性切断花生四烯酸代谢系列中前列腺素环氧合酶的作用,阻断前列腺素E2(PGF2)的合成,进而发挥抗炎、消肿和解热、镇痛作用。其消炎、解热作用比吲哚美辛强2~2.5倍,比阿司匹林强26~50倍。临床主要用于治疗类风湿关节炎、骨关节炎、强直性脊柱炎;各种软组织肿痛,包括腰背痛、肩周炎、滑膜炎、肌腱及腱鞘炎、颈椎病;软组织损伤,包括挫伤、打扑伤、扭伤、撕裂伤、劳损;对红斑狼疮、牙痛、痛经及癌症、手术后疼痛及各种原因引起的发热也有良好的治疗效果。
双氯芬酸钠在国内已有的外用制剂有凝胶剂、乳膏剂、贴剂等,与凝胶剂、乳膏剂等透皮制剂比较,贴剂具有给药次数少,剂量准确的优点。但已见报道的双氯芬酸钠贴剂(双氯芬酸钠透皮控释贴膏,公开日1998年2月25日,公开号1174031A,)经试用其粘力不够,剥离强度实验结果,接合力为80g,远远低于我国医用橡皮膏国家标准和卫生部标准。因而在关节等部位贴敷不紧密,稍加活动即发生移动、变形。因此,有必要寻找一种粘度适宜、与皮肤粘贴牢固、对皮肤无刺激性的双氯芬酸钠外用贴剂。
发明内容:
本发明提供一种使用方便、透皮性能好、与皮肤粘贴牢固而适度、对皮肤无刺激性的双氯芬酸钠贴剂。
本发明双氯芬酸钠贴剂包括背衬层、药物储库及保护膜,药物储库由双氯芬酸钠、压敏胶、渗透促进剂组成。它们的配比如下:(%w/w)
双氯芬酸钠 1-10
压敏胶 40-95
渗透促进剂 1-40
它们的成分分别为:
1.压敏胶可为丙烯酸酯类压敏胶或聚异丁烯类压敏胶,其中:
(1)丙烯酸酯类压敏胶由一个或多个含有4-14个碳原子的烷基丙烯酸酯或烷基甲基丙烯酸酯和丙烯酸或甲基丙烯酸单体共聚而得,压敏胶中加入增塑剂来改善粘附性能,增塑剂选自:①多羟基聚合物,如聚乙二醇;②含有6-20个碳原子的脂肪酸酯,例如琥珀酸酯、癸二酸酯;③脂肪酸,如柠檬酸、琥珀酸等。增塑剂的用量是压敏胶用量的10-50%。可同时选用1-2种增塑剂。
(2)聚异丁烯类压敏胶由一种低分子量聚异丁烯和一种高分子量聚异丁烯混合而成,高分子量的聚异丁烯平均分子量为45万~210万,低分子量聚异丁烯平均分子量为1000~45万,两种聚异丁烯之比例为5-95∶95-5%。低分子量的聚异丁烯在压敏胶中主要起增粘作用和改善胶粘层的柔软性和韧性,改进对基材的润湿性;高分子量的聚异丁烯主要增加压敏胶的剥离强度和内聚强度。
2.渗透促进剂:选自(1)有机溶剂类:如乙醇、丙二醇、脂肪酸酯、二甲基亚砜及其同类物;(2)有机酸、脂肪醇:如油酸、亚油酸、月桂醇;(3)氮酮及其同系物;(4)表面活性剂:选自阳离子型、阴离子型和非离子型,如十二烷基硫酸钠、吐温80;(5)角质保湿与软化剂:如尿素、水杨酸和吡咯烷酮类;(6)萜烯类:如薄荷醇、樟脑、柠檬烯和桉树脑。可同时选用其中的1-3种。
本发明双氯芬酸钠贴剂按前面所列的成分和比例制备,包括下列步骤:
1.制备压敏胶基质(详见实施例)
2.制备双氯芬酸钠贴剂(详见实施例)
将双氯芬酸钠加入上述基质,搅拌使完全溶解;再加入渗透促进剂,使混合均匀,超声去除气泡后涂于背衬,60℃干燥去除溶剂,覆上保护膜。按所需大小切割,密封包装。通常面积为10-100cm2。
上述背衬材料可选自聚乙烯、铝箔、聚丙烯和聚酯等。保护膜材料选自聚乙烯、聚丙烯等。
本发明双氯芬酸钠贴剂的透皮和皮肤刺激性实验:
1.体外透皮实验(方法详见经皮给药新剂型.陆彬主编.药物新剂型与新技术.北京:人民卫生出版社,1998:375)
采用改良Franz扩散池,将小鼠皮肤固定在扩散池上,真皮面向接受室,角质层面向供给室。贴剂贴敷在角质层面,接受室内加入适量PH7.4磷酸盐缓冲液(PBS液)。32℃恒温水浴循环并300转/分磁力搅拌,在2、4、8、12、24小时取样,每次1ml,并立即补充等体积PBS溶液,高效液相色谱法(HPLC)测定样品浓度,结果见表1,其中Q为单位面积累积透过量。
表1双氯芬酸钠贴剂体外透皮实验结果
透皮时间(小时) 2 4 8 12 24
Q(μg/cm2) 20.30 42.81 73.55 135.08 239.85
由表1可见,本发明双氯芬酸钠贴剂透皮速率为10.07μg/cm2·h,24小时累积透过百分率为23.97%,表明本发明双氯芬酸钠贴剂透皮性能良好。
2.粘性实验(方法详见郑俊民主编.经皮给药新剂型.北京:人民卫生出版社,1997)
将不锈钢板表面用有机溶剂清洗,干燥,擦净。将双氯芬酸钠贴剂的保护膜撕去,贴于不锈钢板上,然后在贴剂上用压辊以300mm/分钟的速度压一个往返。放置20分钟后,在贴剂的一端做180℃的折返,同时把粘附部分揭起25mm,接于拉力器上,以300±20mm/分钟的速度连续拉下。拉下时每隔20mm读数一次,共读4次。试验三个不同的贴剂,求取12个测定值的平均值,测定结果平均拉力为150g,说明本发明双氯芬酸钠贴剂的粘性较好,符合国家有关规定。
3.皮肤刺激性实验[方法详见新药(西药)临床前研究指导原则汇编(药学药理学毒理学),中华人民共和国药政局,1993:57,198-208]
3.1皮肤过敏性实验
实验动物:豚鼠40只,雌雄各半,体重300±50g,购自第二军医大学实验动物所。
将豚鼠背部左侧用脱毛剂脱毛,脱毛区面积约3×3cm2,随机分成三组,第一组为阳性对照组,动物14只,给阳性致敏物0.1% 2,4-二硝基氯代苯,(上海试剂一厂生产,用75%乙醇配制);第二组为受试物组,动物13只,给双氯芬酸钠贴剂;第三组为阴性对照组,动物13只,给阴性对照物空白贴剂(除不含双氯芬酸钠外,其余成分与本发明双氯芬酸钠贴剂均相同,下同)。在第一次给药后第7和第14天,以同样方法重复给药一次,每次用药前24小时脱毛。
于末次给受试物致敏后14天(24小时前在豚鼠背部右侧脱毛,面积约3×3cm2),在豚鼠右侧脱毛区以同样方法再分别给药一次(阳性对照组给1%的2,4-二硝基氯代苯),6小时后去掉贴剂,于即刻、24、48和72小时观察皮肤过敏反应情况。结果表明阳性致敏物致敏率为100%,有极强致敏性,双氯芬酸钠贴剂和阴性对照物致敏率为0,均无致敏性,说明双氯芬酸钠贴剂外用于皮肤无致敏性。
3.2皮肤刺激性实验
动物:成年健康家兔8只,雌雄各半,体重2.5-3.0kg,购自第二军医大学实验动物中心。
将实验兔背部脊柱两侧兔毛剪掉,面积约为体表面积的10%(约150cm2),分左右两区,每区约50cm2(5cm×10cm),相邻两区距离约3cm。脱毛24小时后用药,在用药区和对照区分别贴敷双氯芬酸钠贴剂和对照物空白贴剂,24小时去除贴剂,观察用药部位有无红斑和水肿等情况。继续给药,在用药区和对照区分别贴敷双氯芬酸钠贴剂和上述空白贴剂,连续给药一周,去除贴剂后1、24、48和72小时观察用药部位,发现仅1只兔子的用药区略见红斑,且24小时后红斑消失,结果表明双氯芬酸钠贴剂对皮肤无刺激性。
上述试验结果显示本发明双氯芬酸钠贴剂粘贴效果好,对皮肤无刺激和过敏反应,且体外透皮效果良好。
具体实施方式:
现结合实施例,对本发明双氯芬酸钠贴剂及其制备方法作详细描述。
实施例1:制备双氯芬酸钠贴剂,双氯芬酸钠含量1mg/cm2
配方及配比:
双氯芬酸钠 5.0g
甲基丙烯酸和甲基丙烯酸甲酯共聚物 20.0g
柠檬酸三乙酯 6.0g
柠檬酸 0.4g
氮酮 3.0g
异丙醇 6.0g
乙醇 59.6g
制备方法:
1..制备压敏胶基质
按上述配比,将甲基丙烯酸和甲基丙烯酸甲酯共聚物溶解于异丙醇和乙醇组成的混合溶剂;在搅拌下,缓缓加入柠檬酸三乙酯和柠檬酸,搅拌均匀成压敏胶基质。
2.制备双氯芬酸钠贴剂
在上述压敏胶基质中加入双氯芬酸钠,搅拌使完全溶解。再加入氮酮,搅匀。超声去除气泡,涂布于铝箔,60℃干燥20分钟,覆盖聚乙烯膜,切割成50cm2/张,密封包装。本双氯芬酸钠贴剂接合力为120g。
实施例2:制备双氯芬酸钠贴剂,双氯芬酸钠含量1.2mg/cm2
配方及配比:
双氯芬酸钠 5.0g
甲基丙烯酸和甲基丙烯酸甲酯共聚物 36.0g
癸二酸二丁酯 18.0g
琥珀酸 0.4g
氮酮 3.0g
异丙醇 2.0g
乙醇 16g
丙酮 20g
制备方法:
1.制备压敏胶和增塑剂的基质
按上述配比,将甲基丙烯酸和甲基丙烯酸甲酯共聚物溶解于异丙醇、乙醇和丙酮组成的混合溶剂;在搅拌下,缓缓加入癸二酸二丁酯和琥珀酸,搅拌均匀成压敏胶基质。
2.制备双氯芬酸钠贴剂
同实施例1。本双氯芬酸钠贴剂接合力为150g。
实施例3:制备双氯芬酸钠贴剂,双氯芬酸钠含量1mg/cm2
配方及配比:
双氯芬酸钠 5.0g
聚异丁烯MML-100 3.6g
聚异丁烯LM-MS 4.4g
液状石蜡 8.0g
庚烷 76g
氮酮 3.0g
制备方法:
1.制备压敏胶基质
将聚异丁烯MML-100和聚异丁烯LM-MS溶解于庚烷,成压敏胶基质。
2.制备双氯芬酸钠贴剂
双氯芬酸钠过200目筛,以液状石蜡研匀,加入上述压敏胶基质中,搅拌均匀。加入氮酮,搅匀。超声去除气泡,涂布于铝箔,60℃干燥60分钟,覆上聚乙烯膜,切割成50cm2/张,密封包装。本双氯芬酸钠贴剂接合力为130g。
实施例4:制备双氯芬酸钠贴剂,双氯芬酸钠含量1mg/cm2
配方及配比:
双氯芬酸钠 6.0g
甲基丙烯酸和甲基丙烯酸甲酯共聚物 24.0g
癸二酸二丁酯 18.0g
琥珀酸 0.4g
樟脑 3.0g
异丙醇 2.0g
乙醇 16g
丙酮 31g
制备方法:
1.制备压敏胶基质
同实施例2。
2.制备双氯芬酸钠贴剂
在上述压敏胶基质中加入双氯芬酸钠,搅拌使完全溶解。再加入樟脑,搅匀。超声去除气泡,涂布于铝箔,60℃干燥20分钟,覆上聚乙烯膜,切割成50cm2/张,密封包装。本双氯芬酸钠贴剂接合力为160g。
实施例5:制备双氯芬酸钠贴剂,双氯芬酸钠含量1.5mg/cm2
配方及配比:
双氯芬酸钠 8.0g
聚异丁烯MML-100 2.4g
聚异丁烯LM-MS 5.6g
液状石蜡 8.0g
庚烷 73g
氮酮 3.0g
制备方法同实施例3。
本双氯芬酸钠贴剂接合力为120g。
Claims (4)
1、一种双氯芬酸钠贴剂,包括背衬层、药物储库及保护膜,其特征在于药物储库由双氯芬酸钠、压敏胶、渗透促进剂组成,配比如下:(%w/w)
双氯芬酸钠 1-10
压敏胶 40-95
渗透促进剂 1-40
2、按权利要求1所述的双氯芬酸钠贴剂,其特征在于所说的压敏胶可为丙烯酸酯类压敏胶或聚异丁烯类压敏胶,其中,丙烯酸酯类压敏胶由一个或多个含有4-14个碳原子的烷基丙烯酸酯或烷基甲基丙烯酸酯和丙烯酸或甲基丙烯酸单体共聚而得,压敏胶中加入增塑剂来改善粘附性能,增塑剂选自聚乙二醇、琥珀酸酯、癸二酸酯、柠檬酸酯、柠檬酸、琥珀酸,可同时选用1-2种增塑剂。
3、按权利要求2所述的双氯芬酸钠贴剂,其特征在于所说的聚异丁烯类压敏胶由一种低分子量聚异丁烯和一种高分子量的聚异丁烯混合组成,低分子量和高分子量聚异丁烯的比例为5-95∶95-5%。
4、按权利要求1、2、3所述的双氯芬酸钠贴剂,其特征在于所说的渗透促进剂选自乙醇、丙二醇、脂肪酸酯、二甲基亚砜、油酸、亚油酸、月桂醇、氮酮、十二烷基硫酸钠、吐温80、尿素、水杨酸和N-甲基吡咯烷酮、N-乙基吡咯烷酮、薄荷醇、樟脑、柠檬烯和桉树脑,可同时选用1-3种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03129503 CN1215838C (zh) | 2003-06-25 | 2003-06-25 | 双氯芬酸钠贴剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03129503 CN1215838C (zh) | 2003-06-25 | 2003-06-25 | 双氯芬酸钠贴剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1489996A true CN1489996A (zh) | 2004-04-21 |
CN1215838C CN1215838C (zh) | 2005-08-24 |
Family
ID=34153555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03129503 Expired - Lifetime CN1215838C (zh) | 2003-06-25 | 2003-06-25 | 双氯芬酸钠贴剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1215838C (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895242B (zh) * | 2006-04-13 | 2011-08-31 | 沈阳药科大学 | 双氯芬酸盐的透皮贴剂及制备方法 |
CN102186468A (zh) * | 2008-10-21 | 2011-09-14 | 皮埃尔·法布尔皮肤化妆品公司 | 治疗甲银屑病的基于尿素的成膜溶液 |
CN102791267A (zh) * | 2010-01-07 | 2012-11-21 | 帝国制药株式会社 | 消炎镇痛外用贴剂 |
CN101157612B (zh) * | 2007-11-13 | 2013-05-29 | 沈阳药科大学 | 一类有机酸的薄荷醇衍生物及含有该衍生物的经皮给药制剂 |
CN104547472A (zh) * | 2014-12-10 | 2015-04-29 | 深圳先进技术研究院 | 一种治疗类风湿性关节炎的药物组合物、制备方法及其贴剂 |
CN105250243A (zh) * | 2015-11-06 | 2016-01-20 | 中国药科大学 | 一种长效黏胶分散型透皮贴剂及其制备工艺 |
CN105326818A (zh) * | 2015-11-27 | 2016-02-17 | 四川理工学院 | 一种新型双氯酚酸钠贴剂 |
EP2865378A4 (en) * | 2012-06-20 | 2016-03-02 | Hisamitsu Pharmaceutical Co | SKIN PATCH |
CN105708823A (zh) * | 2016-04-08 | 2016-06-29 | 中国药科大学 | 一种长效双氯芬酸类透皮贴剂及其制备工艺 |
CN107669661A (zh) * | 2016-12-12 | 2018-02-09 | 青岛大学 | 双氯芬酸钠透皮贴剂 |
CN111821285A (zh) * | 2020-06-17 | 2020-10-27 | 南京海纳医药科技股份有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
WO2021234562A1 (en) * | 2020-05-20 | 2021-11-25 | Fidia Farmaceutici S.P.A. | Slow-release medical plaster |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
-
2003
- 2003-06-25 CN CN 03129503 patent/CN1215838C/zh not_active Expired - Lifetime
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1895242B (zh) * | 2006-04-13 | 2011-08-31 | 沈阳药科大学 | 双氯芬酸盐的透皮贴剂及制备方法 |
CN101157612B (zh) * | 2007-11-13 | 2013-05-29 | 沈阳药科大学 | 一类有机酸的薄荷醇衍生物及含有该衍生物的经皮给药制剂 |
CN102186468A (zh) * | 2008-10-21 | 2011-09-14 | 皮埃尔·法布尔皮肤化妆品公司 | 治疗甲银屑病的基于尿素的成膜溶液 |
CN102186468B (zh) * | 2008-10-21 | 2014-02-12 | 皮埃尔·法布尔皮肤化妆品公司 | 治疗甲银屑病的基于尿素的成膜溶液 |
CN102791267A (zh) * | 2010-01-07 | 2012-11-21 | 帝国制药株式会社 | 消炎镇痛外用贴剂 |
US8657798B2 (en) | 2010-01-07 | 2014-02-25 | Teikoku Seiyaku Co., Ltd. | Anti-inflammatory analgesic adhesive patch for external use |
CN102791267B (zh) * | 2010-01-07 | 2015-06-10 | 帝国制药株式会社 | 消炎镇痛外用贴剂 |
EP2865378A4 (en) * | 2012-06-20 | 2016-03-02 | Hisamitsu Pharmaceutical Co | SKIN PATCH |
US9308187B2 (en) | 2012-06-20 | 2016-04-12 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive patch comprising diclofenac sodium |
CN104547472A (zh) * | 2014-12-10 | 2015-04-29 | 深圳先进技术研究院 | 一种治疗类风湿性关节炎的药物组合物、制备方法及其贴剂 |
CN105250243A (zh) * | 2015-11-06 | 2016-01-20 | 中国药科大学 | 一种长效黏胶分散型透皮贴剂及其制备工艺 |
CN105326818A (zh) * | 2015-11-27 | 2016-02-17 | 四川理工学院 | 一种新型双氯酚酸钠贴剂 |
CN105326818B (zh) * | 2015-11-27 | 2018-05-25 | 四川理工学院 | 一种双氯酚酸钠贴剂 |
CN105708823A (zh) * | 2016-04-08 | 2016-06-29 | 中国药科大学 | 一种长效双氯芬酸类透皮贴剂及其制备工艺 |
CN107669661A (zh) * | 2016-12-12 | 2018-02-09 | 青岛大学 | 双氯芬酸钠透皮贴剂 |
CN107669661B (zh) * | 2016-12-12 | 2020-05-26 | 山东朱氏药业集团有限公司 | 双氯芬酸钠透皮贴剂 |
IE20210109A1 (en) * | 2020-05-20 | 2022-08-17 | Fidia Farm Spa | Slow-release medical plaster |
WO2021234562A1 (en) * | 2020-05-20 | 2021-11-25 | Fidia Farmaceutici S.P.A. | Slow-release medical plaster |
NL2028233A (en) * | 2020-05-20 | 2021-12-01 | Fidia Farm Spa | Slow-release medical plaster |
BE1028251B1 (fr) * | 2020-05-20 | 2022-04-05 | Fidia Farm Spa | Emplâtre médical à libération lente |
GB2610106A (en) * | 2020-05-20 | 2023-02-22 | Fidia Farm Spa | Slow-release medical plaster |
PL442805A1 (pl) * | 2020-05-20 | 2023-07-03 | Fidia Farmaceutici S.P.A | Przylepiec medyczny o powolnym uwalnianiu |
ES2936185R1 (es) * | 2020-05-20 | 2023-10-11 | Fidia Farm Spa | Apósito médico de liberación lenta |
GB2610106B (en) * | 2020-05-20 | 2024-08-07 | Fidia Farm Spa | Slow-release medical plaster |
PL245596B1 (pl) * | 2020-05-20 | 2024-09-02 | Fidia Farm Spa | Przylepiec medyczny i jego zastosowanie oraz matryca kleju przylepcowego |
CN111821285A (zh) * | 2020-06-17 | 2020-10-27 | 南京海纳医药科技股份有限公司 | 一种含双氯芬酸依泊胺的透皮贴剂及其制备方法 |
US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Also Published As
Publication number | Publication date |
---|---|
CN1215838C (zh) | 2005-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1239203C (zh) | 用于透皮药物释放的水凝胶组合物 | |
CN1215838C (zh) | 双氯芬酸钠贴剂及其制备方法 | |
JP5702434B2 (ja) | 経皮薬物送達システムにおいて有用な非反応型接着剤 | |
CN1143688C (zh) | 透皮促进剂甘油三醋酸酯 | |
JP5155900B2 (ja) | 架橋型皮膚用粘着剤 | |
CN1231592A (zh) | 作为渗透促进剂的羟乙酸及其盐的脂肪酸酯 | |
CN87105953A (zh) | 外用带状贴剂的局部消炎止痛的药用组合物的制备方法 | |
CN1424908A (zh) | 含有抗炎药的贴剂 | |
JPS61502760A (ja) | 粘着性経皮投与層 | |
CN1420770A (zh) | 递送肉豆蔻脑酸十六醇酯的方法 | |
CN101322853A (zh) | 凝胶组合物和它们的用途 | |
JP4272636B2 (ja) | 架橋型皮膚用粘着剤 | |
WO2008032718A1 (fr) | Préparation adhésive | |
TW201102111A (en) | Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome | |
TW201438767A (zh) | 用於經皮傳遞非類固醇抗發炎劑之組合物及方法 | |
CN1827094A (zh) | 一种凝胶型右旋酮洛芬贴剂及其制备方法 | |
JPH0662401B2 (ja) | ケトプロフエン含有パツプ剤 | |
CN1400897A (zh) | Lasofoxifene的经皮转运 | |
CN1056055A (zh) | 经皮吸收的乙苯哌丁酮和甲苯哌丙酮制剂 | |
JP5059408B2 (ja) | 爪用外用剤 | |
JPH08310946A (ja) | 経皮吸収製剤 | |
HU203280B (en) | Process for producing means containing transdermal nor-pseudo-ephedrine as active component | |
JPH0339488B2 (zh) | ||
CN1309553A (zh) | 生物活性组合物 | |
CN102970986B (zh) | 含有吡罗昔康的骨架型贴剂以及局部治疗急性和慢性疼痛及其相关炎症的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
C49 | Reinstatement of patent right or utility model | ||
RR01 | Reinstatement of patent right | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050824 |